PanACEA’s MAMS study continues to enroll patients rapidly. By mid-October more than 200 of the required 372 patients have been enrolled. Recruitment is thus ahead of target.
MAMS study sites rapidly enrolling patients
PanACEA’s MAMS study continues to enroll patients rapidly. By mid-October more than 200 of the required 372 patients have been enrolled. Recruitment is thus ahead of target.